Please assess the completion status of the following clinical trial:

Trial Title: Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* New York Heart Association (NYHA) Functional class Ⅲ or Ⅳ~* Left Ventricular Ejection Fraction (LVEF) \<35%~* Nonischemic cardiomyopathy~* Preserved renal function: Cr ≤2.5 mg/dL in males; Cr ≤2.0mg/dL in females~Exclusion Criteria:~* Hyperkalemia (≥5.0 mEg/L)~* Left ventricular systolic dysfunction with pericardial diseases, congenital heart diseases, pulmonary heart diseases, heart valvular diseases, acute coronary syndrome and short life expectancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).